Myriad Genetics, Inc. MYGN recently announced an agreement with Personalis, Inc. to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease (MRD).

The data shows the prognostic value of Foresight CLARITY MRD detection at the end of frontline DLBCL in one of its largest prospective, real-world studies to date Data will be presented as an oral ...

The assay leverages the same powerful technology as prior versions, detecting MRD by reading the full immune receptor sequence of the malignant B cells rather than relying on individual point ...